DOCSLIB.ORG

Targeting the Cellular Schizophrenia. Likely Employment of the Antipsychotic Agent Pimozide in Treatment of Refractory Cancers A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Targeting the Cellular Schizophrenia. Likely Employment of the Antipsychotic Agent Pimozide in Treatment of Refractory Cancers A Critical Reviews in Oncology / Hematology 128 (2018) 96–109 Contents lists available at ScienceDirect Critical Reviews in Oncology / Hematology journal homepage: www.elsevier.com/locate/critrevonc Targeting the cellular schizophrenia. Likely employment of the T antipsychotic agent pimozide in treatment of refractory cancers and glioblastoma ⁎ Ilhan Elmacia, Meric A. Altinozb,c, a Memorial University, Neuroacademy Group, Istanbul, Turkey b Neurooncology Branch, Neuroacademy Group, Istanbul, Turkey c Department of Psychiatry, Maastricht University, Holland, Turkey ARTICLE INFO ABSTRACT Keywords: Pimozide is currently being used in clinic as a neuroleptic and exerts versatile biological actions. Pimozide is a Pimozide cationic amphiphilic drug (CAD); CADs block the synthesis of neutral lipids, impair cholesterol homeostasis of Refractory cancers cancer cells and increase accumulation of diacylglycerol-3-phosphate. Pimozide exerts tumoricidal activity Glioblastoma which was first shown for melanoma and neuroblastoma via proposed anti- dopaminergic effects. Recently, pancreas cancers are shown to elevate dopamine receptor-2 synthesis, which is blocked by pimozide leading growth inhibition. Besides binding to inner mitochondrial membrane and reducing cellular respiration, pimozide also inhibits calmodulin, T-type calcium channels and σ-receptors which all correlate with tumor-inhibitory functions. Pimozide also exerts chemotherapy and radiotherapy-sensitizing effects in cancer cells and acts as an inhibitor of STAT-3 and STAT-5 signaling proteins with potential activity in leukemia, liver and prostate cancer. Pimozide also blocks stem cell features and Wnt-β/catenin signaling in liver cancer. Pimozide interferes with Fatty Acid Protein Binding-4 and activates PPAR-γ and it was proposed to alleviate cancer cachexia. Besides mechanisms of calmodulin and σ-receptor associated pathways, pimozide was proposed to inhibit glioblastoma via serotonin receptor 5-HT7. Pimozide is a selective inducer of autophagy and also inhibits ubiquitine specific protease (USP-1) which may associate with its chemosensizing potential in lung cancer and glioblastoma. Via versatile mechanisms of tumoricidal actions and due to its highly traversing capability through the blood-brain barrier, pimozide highly deserves to be studied in animal models of drug resistant refractory cancers and glioblastoma, which have very poor prognosis. 1. Introduction. The cancer problem and targeting cancer with et al., 2017). Hence, there is an urgent need to develop novel innovative Neuroleptic/ antipsychotic drugs strategies to treat metastatic and chemorefractory cancers, cancers with a generally poor prognosis (eg. pancreas and lung cancers) and glio- Despite immense efforts to discover novel anticancer agents; in blastomas. Interestingly, many studies showed decreased risk of cancer 2012, about 14.1 million new cases of cancer occurred globally, causing in schizophrenia patients; and despite most of these patients smoke around 8.2 million deaths (World Cancer heavily, metaanalysis studies also found that the pooled overall cancer Report 2014. World Health Organization (WHO) 2014. pp. Chapter incidence rates for patients with schizophrenia did not parallel their 1.1; The top 10 causes of death Fact sheet No:310. WHO. 2014). The cancer risk factor exposure (Wiklund et al., 2010). Very noteworthy, a financial costs of cancer were estimated at $1.16 trillion US dollars per comprehensive in vivo screen of 297 central nervous system acting year as of 2010 (World Cancer Report 2014. WHO. 2014. pp. Chapter compounds revealed 6.7). Many agents were developed to block the growth of malignancies, that psychoactive agents were 18-fold more likely to exert anti- yet metastatic cancers are systemic diseases which remain manageable proliferative potential when compared with a random population of but incurable. Glioblastomas have the highest incidence among primary molecules (Wiklund et al., 2010). Many subsequent investigations on brain tumors, second only to meningioma with a very poor prognosis (a cancer cell lines confirmed that especially neuroleptic agents as a class 5-year survival rate of about 4% from the time of diagnosis) (Altinoz possesed cytotoxic potential. Tumoricidal actions occurred in a wide ⁎ Corresponding author at: Nurtepe Mh. Guven Sk. No:5, D:6 Kagithane, Istanbul, Turkey. E-mail address: [email protected] (M.A. Altinoz). https://doi.org/10.1016/j.critrevonc.2018.06.004 Received 20 February 2018; Received in revised form 16 May 2018; Accepted 6 June 2018 1040-8428/ © 2018 Elsevier B.V. All rights reserved. I. Elmaci, M.A. Altinoz Critical Reviews in Oncology / Hematology 128 (2018) 96–109 dopamine D2 receptor with a high affinity, which causes both adverse effects (eg. extrapyramidal) and therapeuticity against the positive symptoms of schizophrenia. But as will be suggested, pimozide seems also to act beneficial on negative symptoms of schizophrenia in contrast to other typical neuroleptics. The side effects of pimozide include akathisia, tardive dyskinesia, prolongation of the QT interval, and rarely, neuroleptic malignant syndrome (Zemrak and Kenna, 2008). Diphenylbutylpiperidine class neuroleptics (Fig. 3) including pi- mozide, fluspirilene, penfluridol, and clopimozide, exert structural si- milarity to verapamil-like Ca+2-channel antagonists and inhibit 3H-ni- trendipine binding with IC50 values of 13–30 nM (nitrendipine is a dihydropyridine class Ca+2-channel antagonist) (Gould et al., 1983). This inhibition involves receptors for the verapamil/prenylamine class of Ca+2-channel antagonists. These diphenylbutylpiperidines also in- hibit K+-induced Ca+2-dependent contractions of rat vas deferens at concentrations of 40–350 nM. Other phenothiazine and butyrophenone neuroleptics lack such potent Ca+2-antagonist actions (Gould et al., 1983). As suggested, diphenylbutylpiperidines also differ from other typical neuroleptics in their efficacy to relieve negative symptoms of schizophrenia, such as emotional withdrawal, which were proposed to relate to an inhibition of voltage-operated Ca+2 channels (Gould et al., 1983). T-type (“T” for transient) Ca+2 channels are low-voltage activated Ca+2-channels that open during membrane depolarization and are ex- Fig. 1. Molecular Structure of Pimozide. pressed in diverse tissues, including neuronal, cardiovascular, and en- docrine, which regulate the development, maintenance, and repair of range of human cancer cell lines, including those employed in the these tissues (Kopecky et al., 2014). Although low-voltage-activated +2 National Cancer Institute’s screening program, and first generation Ca -channels have limited amino acid homology to the high-voltage- +2 antipsychotics generally appeared to be more cytotoxic than second activated Ca -channel families, which include L-type channels, all +2 generation antipsychotics (Wiklund et al., 2010). The repurposing of voltage-gated Ca -channels are structurally related (Uebele et al., +2 “ ” non-cancer drugs by 2009). The L-type Ca -channel ( L for long-lasting) is part of the +2 screening for novel anti-cancer activity is a plausible and powerful high-voltage activated family of voltage-dependent Ca channels. L- 2+ strategy to fastly determine new cancer therapeutics from the known type Ca channels (Cav1) represent one of the three major classes – +2 pool of small molecules that have already undergone rigorous tests via (Cav1 3) of voltage-gated Ca -channels as the target of clinically used +2 clinical trials for human safety, thus potentially fast-tracking the de- Ca -channel blockers including dihydropyridines (Striessnig et al., velopment and approval process, while reducing life-threatening risks 2014). In almost all electrically excitable cells one or more of these L- 2+ (Fako et al., 2016). In this manuscript, we will discuss the powerful type Ca channels isoforms is expressed. Hence, diverse functions potentials of the neuroleptic pimozide (Fig. 1) as a novel anticancer including muscle, brain, endocrine, and sensory functions depend on 2+ agent against refractory cancers and glioblastoma. proper L-type Ca channels activity and even small changes of their expression or activity may be associated with psychiatric disease or cardiac arrhythmias (Striessnig et al., 2014). Pimozide is a potent in- 2. Pimozide. Chemical structure and interactions with cellular hibitor of T-type Ca2+ channels but with less selectivity than mibe- biology fradil; in pituitary and heart cells, pimozide inhibits L-type Ca2+ channels, whereas in adrenal glomerulosa and spermatogenic cells, it Antipsychotics also known as neuroleptics or major tranquilizers, blocks T channels and Ca2+ influx (Bertolesi et al., 2002). The actions are medicines primarily employed to treat psychosis principally in of pimozide and mibefradil are not restricted to Ca2+ channels but may − schizophrenia (the terms “neuroleptic” and “antipsychotic” are used also affect other ion channels, including K+ and Cl channels (Bertolesi interchangeably in this review). Pimozide (depicted in Fig. 1)isa et al., 2002). neuroleptic of the diphenylbutylpiperidine class which was discovered Pimozide is a strong inhibitor of dopamine as well as the release of in 1963 by the physician Paul Janssen (Awouters and Lewi, 2007; melanocyte stimulating hormone (MSH), corticotropin releasing factor Mothi and Sampson, 2013). Pimozide has neuropsychiatric indications and gonadotropin releasing hormone (GnRH) in rats (Krummel et al., for paranoid personality disorder,
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al
    US 2011 01 05536A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe et al. (43) Pub. Date: May 5, 2011 (54) DOSING REGIMENASSOCATED WITH Publication Classification LONG-ACTING INUECTABLE PALIPERDONE ESTERS (51) Int. Cl. A 6LX 3/59 (2006.01) (76) Inventors: Peter H. Lewyn-Briscoe, A6IP 25/18 (2006.01) Newtown, PA (US); Cristiana Gassmann-Mayer, Pennington, NJ (US); Srihari Gopal, Belle Meade, (52) U.S. Cl. ................................................... S14/259.41 NJ (US); David W. Hough, Wallingford, PA (US); Bart M.M. Remmerie, Gent (BE); Mahesh N. (57) ABSTRACT Samtani, Flemington, NJ (US) The present application provides a method for treating (21) Appl. No.: 12/916,910 patients in need of psychiatric treatment, wherein said patient (22) Filed: Nov. 1, 2010 misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides Related U.S. Application Data a method for treating psychiatric patients in need of a Switch (60) Provisional application No. 61/256,696, filed on Oct. ing treatment to paliperidone palmitate in a Sustained release 30, 2009. formulation. Patent Application Publication May 5, 2011 Sheet 1 of 6 US 2011/O105536 A1 FIG. 1 First-Order PrOCeSS Cp V CL Central (2) Zero-Order PrOCeSS Patent Application Publication May 5, 2011 Sheet 2 of 6 US 2011/O105536 A1 FIG. 2 25mgeq 50mgeq m-100mde::::: Missed doSe On WK 4. Patient returns On WK5 Missed doSe On WK 4. Patient returns On WK 6 -8-4 O 4 8 12 16 2024 -8-4 O 4 8 12 1620 24 Missed doSe On WK 4.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • The Influence of Psychoactive Drugs on Brain Self-Stimulation Behaviour
    PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/147779 Please be advised that this information was generated on 2021-10-04 and may be subject to change. The influence of psychoactive drugs on brain self-stimulation behaviour A. Wauquier The influence of psychoactive drugs on brain self-stimulation behaviour A. Wauquier D/1976/1060/65 Promotores: Prof. Dr. J.M.H. VOSSEN Prof. Dr. J.M. VAN ROSSUM The influence of psychoactive drugs on brain self-stimulation behaviour Proefschrift ter verkrijging van de graad van doctor in de Sociale Wetenschappen aan de Katholieke Universiteit te Nijmegen, op gezag van de Rector Magnificus prof. dr. A.J.H. Vendrik volgens besluit van het College van Decanen in het openbaar te verdedigen op vrijdag 8 oktober 1976 des namiddags te 4.00 uur door ALBERT WAUQUIER geboren te Menen Drukkerij Daneels, Beerse, Belgium 1976 3 Aan Annie 4 Acknowledgements The author would like to thank all those who have contributed to the realization of this study whether or not they are explicitly mentioned here. The assistance of Dr. P.A.J. Janssen in providing the opportunity to perform the experiments in optimal conditions in his laboratory is grate­ fully acknowledged. His interest and suggestions have stimulated much of the present work. Dr. C.J .E. Niemegeers's constructive criticism of many of the experiments has been much appreciated. It is to him that I owe my education in the field of pharmacology.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley Et Al
    USOO6197764B1 (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley et al. (45) Date of Patent: *Mar. 6, 2001 (54) CLOZAPINE COMPOSITIONS AND USES FOREIGN PATENT DOCUMENTS THEREOF 0599 576A1 1/1994 (EP). (75) Inventors: Matthews O. Bradley, Laytonsville, 693498 1/1996 (EP). MD (US); Victor E. Shashoua, 61204136 11/1984 (JP). Belmont, MA (US); Charles S. 06-072868 3/1994 (JP). Swindell, Merion; Nigel L. Webb, 6072868 3/1994 (JP). Bryn Mawr, both of PA (US) 7082146 3/1996 (JP). 8151334 6/1996 (JP). (73) Assignee: Protarga, Inc., Conshohocken, PA (US) 9030963 2/1997 (JP). (*) Notice: Subject to any disclaimer, the term of this WO 89/07938 9/1989 (WO). patent is extended or adjusted under 35 WO 96/04001 2/1996 (WO). U.S.C. 154(b) by 0 days. WO 96/22303 7/1996 (WO). WO 96/27380 9/1996 (WO). This patent is Subject to a terminal dis WO98/17325 4/1998 (WO). claimer. OTHER PUBLICATIONS (21) Appl. No.: 08/978,541 (22) Filed: Nov. 26, 1997 Bourat, et al., "Long Chain Esters of Pipotiazine as Lon g-Acting Psychotropic Pro-Drug, Med. Chem. Proc. Int. (51) Int. Cl. .............................................. A61K 31/00 Symp. 5th (1976) pp. 105-114. (52) U.S. Cl. ........................... 514/218; 514/219; 514/220 Lohr, et al., “Neuroleptic-Induced Movement Disorders . (58) Field of Search ..................................... 514/218, 219, ..", Psychiatry, vol. 3, (1989). 514/220 Makino, et al., Chemical Abstracts, vol. 106, No. 12, (56) References Cited (90.177x) issued Mar. 23, 1987, “Pharmaceuticals Permeable to Blood-Brain Barrier'.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al
    US 2008O161324A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen et al. (43) Pub. Date: Jul. 3, 2008 (54) COMPOSITIONS AND METHODS FOR Publication Classification TREATMENT OF VRAL DISEASES (51) Int. Cl. (76) Inventors: Lisa M. Johansen, Belmont, MA A63/495 (2006.01) (US); Christopher M. Owens, A63L/35 (2006.01) Cambridge, MA (US); Christina CI2O I/68 (2006.01) Mawhinney, Jamaica Plain, MA A63L/404 (2006.01) (US); Todd W. Chappell, Boston, A63L/35 (2006.01) MA (US); Alexander T. Brown, A63/4965 (2006.01) Watertown, MA (US); Michael G. A6II 3L/21 (2006.01) Frank, Boston, MA (US); Ralf A6IP3L/20 (2006.01) Altmeyer, Singapore (SG) (52) U.S. Cl. ........ 514/255.03: 514/647; 435/6: 514/415; Correspondence Address: 514/460, 514/275: 514/529 CLARK & ELBNG LLP 101 FEDERAL STREET BOSTON, MA 02110 (57) ABSTRACT (21) Appl. No.: 11/900,893 The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain (22) Filed: Sep. 13, 2007 embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particu Related U.S. Application Data lar embodiments, the viral disease is viral hepatitis (e.g., (60) Provisional application No. 60/844,463, filed on Sep. hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). 14, 2006, provisional application No. 60/874.061, Also featured are screening methods for identification of filed on Dec. 11, 2006. novel compounds that may be used to treat a viral disease.
    [Show full text]
  • Antipsychotics for Treatment of Delirium in Hospitalised Non-ICU Patients
    This is a repository copy of Antipsychotics for treatment of delirium in hospitalised non-ICU patients. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/132847/ Version: Published Version Article: Burry, Lisa, Mehta, S.R., Perreault, M.M et al. (6 more authors) (2018) Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews. CD005594. ISSN 1469-493X https://doi.org/10.1002/14651858.CD005594.pub3 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Antipsychotics for treatment of delirium in hospitalised non- ICU patients (Review) Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews 2018, Issue 6.
    [Show full text]
  • Zebrafish Behavioral Profiling Identifies Multi-Target Antipsychotic-Like Compounds
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE HHS Public Access provided by Carolina Digital Repository Author manuscript Author ManuscriptAuthor Manuscript Author Nat Chem Manuscript Author Biol. Author Manuscript Author manuscript; available in PMC 2016 November 30. Published in final edited form as: Nat Chem Biol. 2016 July ; 12(7): 559–566. doi:10.1038/nchembio.2097. Zebrafish behavioral profiling identifies multi-target antipsychotic-like compounds Giancarlo Bruni1,†, Andrew J. Rennekamp1,2,†, Andrea Velenich3,†, Matthew McCarroll4,5, Leo Gendelev5,9, Ethan Fertsch4,5, Jack Taylor4,5, Parth Lakhani4,5, Dennis Lensen3, Tama Evron3, Paul J. Lorello6, Xi-Ping Huang7, Sabine Kolczewski8, Galen Carey3, Barbara J. Caldarone6, Eric Prinssen8, Bryan L. Roth7, Michael J. Keiser5,9, Randall T. Peterson1,2, and David Kokel4,5 1Cardiovascular Research Center and Division of Cardiology, Department of Medicine, Massachusetts General Hospital and Department of Systems Biology, Harvard Medical School, 149 13th Street, Charlestown, Massachusetts, 02129, USA 2Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA 3Teleos Therapeutics, 196 Boston Avenue, Suite 2400, Medford, MA 02155, USA 4Department of Physiology, University of California, San Francisco, California 94158, USA 5Institute for Neurodegenerative Disease, University of California, San Francisco, California 94143, USA 6NeuroBehavior Laboratory, Harvard NeuroDiscovery Center and Department of Neurology, Brigham and Women’s Hospital, 77 Avenue
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Developing a Neuronal Model for the Pathophysiology of Schizophrenia Based on the Nature of Electrophysiological Actions of Dopa
    REVIEW Developing a Neuronal Model for the Pathophysiology of Schizophrenia Based on the Nature of Electrophysiological Actions of Dopamine in the Prefrontal Cortex Charles R. Yang, Ph.D., Jeremy K. Seamans, Ph.D., and Natalia Gorelova, Ph.D. This review covers some recent findings of the same schizophrenic patient in the course of the illness. We electrophysiological mechanisms through which hypothesize that the dysfunctional mesocortical dopamine mesocortical dopamine modulates prefrontal cortical input to the PFC may lead to abnormal modulation of neurons. Dopamine has been shown to modulate several ionic channels distributed in the dendritic–somatic ionic conductances located along the soma-dendritic axis of compartments of PFC pyramidal neurons that project to the prefrontal cortical pyramidal neurons. These ionic currents ventral tegmental area and/or nucleus accumbens. In some include high-voltage-activated calcium currents and slowly schizophrenics, a reduction of mesocortical dopamine to inactivating Na1 and K1 currents. They contribute actively below optimal levels and/or a loss of local GABAergic in processing functionally segregated inputs during inputs may result in a dysfunctional integration of extrinsic synaptic integration. In addition, dopamine mainly associative inputs by Ca21 channel activity in the distal depolarizes the fast-spiking subtype of local GABAergic dendrites of PFC pyramidal neurons. This may account for interneurons that connect the pyramidal neurons. This the patients’ distractibility caused by their inability to focus latter action can indirectly control pyramidal cell only on relevant external inputs. In contrast, in acute stress excitability. These electrophysiological data indicate that the or psychotic episodes, an associated abnormal elevation of actions of dopamine are neither “excitatory” nor mesocortical dopamine transmission may greatly influence “inhibitory” in pyramidal prefrontal cortex neurons.
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]